Abstract: An apparatus for use in aerosol delivery has a housing with a first rigid shell; a second rigid shell; and a deformable band coupling the first and the second rigid shells together to allow axial translation therebetween while advantageously preventing the ingress of debris or other contaminants into the housing. The housing has a cavity sized to accommodate a spray bottle therein. Pinching the rigid shells of the housing together causes operative engagement of a piston or pump of the spray bottle to dispense an aerosol, for instance to hydrate and/or deliver a physiological salt (e.g., CaCl2) to an upper respiratory tract. The housing may allow replacement of the spray bottle (e.g., sterile fill reservoir), for instance as the contents thereof are depleted. Registration features can ensure that a nozzle of the spray bottle aligns with a port in the housing.

Abstract: Hydration of a larynx and/or vicinity with a composition comprising a salt formulation (e.g., CaCl2, MgCl2, KCl and/or NaCl) can achieve prophylactic and/or therapeutic effects (e.g., cough suppression, improving voice quality, increasing pulse oxygen saturation and/or increasing mucosal vaccination effectiveness). The composition is administered as dry particles (e.g., aerosol) or as a liquid (e.g., solution, aerosol). The liquid can have a pH of 7.0 up to around 10.0, or preferably around 7.5 up to around 9.5, or more preferably around 8.0 up to around 9.0, or even more preferably 8.0 to 8.5 or most preferably around 8.0. The droplets can have a mass median aerodynamic diameter from approximately 8 ?m to approximately 15 ?m or from approximately 15 ?m to approximately 500 ?m. A therapeutic dose (e.g., 0.5 mg to 4.0 mg mass of salt) is administered in response to an indication. Such can employ an osmolitically active composition.

Abstract: Hydration of a larynx and/or vicinity with a composition comprising a salt formulation (e.g., CaCl2, MgCl2, KCl and/or NaCl) can achieve prophylactic and/or therapeutic effects (e.g., cough suppression, improving voice quality, increasing pulse oxygen saturation and/or increasing mucosal vaccination effectiveness). The composition is administered as dry particles (e.g., aerosol) or as a liquid (e.g., solution, aerosol). The liquid can have a pH of 7.0 up to around 10.0, or preferably around 7.5 up to around 9.5, or more preferably around 8.0 up to around 9.0, or even more preferably 8.0 to 8.5 or most preferably around 8.0. The droplets can have a mass median aerodynamic diameter from approximately 8 ?m to approximately 15 ?m or from approximately 15 ?m to approximately 500 ?m. A therapeutic dose (e.g., 0.5 mg to 4.0 mg mass of salt) is administered in response to an indication. Such can employ an osmolitically active composition.

Abstract: A composition of food or therapeutic and other substances for administration as a cloud of droplets, the cloud comprising readily-soluble droplets having a median size range of approximately 3 microns to approximately 20 microns, or 5 microns to 10 microns, or 6 microns to 10 microns, for introduction to an animal via an ortho-nasal or retro-nasal route. Agonists or antagonists may include one or more of the following: sodium iodide, sodium chloride, magnesium chloride, capsaicin, piperine, linalool, ground cinnamon, a cannabinoid, pimento, onion, clove, thyme, ginger, menthol, or TRPV antagonists, and chocolate, Irish cream, caramel, lemon, lime, mango, raspberry, watermelon, blueberry, strawberry, mint, popcorn, meat, Resolvin D2 or nicotine. Devices for delivering compositions as an aerosol are described.